Immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1), and other inhibitors, have also been utilized in the second-line treatment of HCC (27, 28). Here, PDCD1 is linked to hepatocellular carcinoma.